Công ty Y tế AiKe, sau năm 75, Giám đốc điều hành Ding Lin kiêm Trưởng phòng tài chính, có hồ sơ bao gồm Ngân hàng Citibank và Fosun High Tech

**瑞财经 刘治颖 **3月24日，艾柯医疗器械（北京）股份有限公司（以下简称“艾柯医疗”）科创板IPO获受理，保荐机构为中信证券，保荐代表人为陈溦、马翔，会计师事务所为安永华明。

According to 瑞财社, this is艾柯医疗’s second attempt at an IPO, having previously applied for the 科创板 IPO on April 20, 2023, which was terminated on April 11, 2024, after one round of inquiry responses.

艾柯医疗 was established in August 2017, with a registered capital of 43.0842 million yuan. It is a national high-tech enterprise in the commercialization stage, focusing on innovative medical devices in the field of neurointervention, integrating R&D, production, and commercialization. It has also been recognized as a national “little giant” specialized and innovative enterprise.

As of the date of signing the prospectus,艾柯医疗 has had ten types of Class III medical devices approved in China, including innovative medical devices such as the Lattice® flow-directed mesh stent, Grism® distal closure intracranial thrombectomy stent, and Attractor® intracranial thrombus suction catheter, with products also being approved or registered in overseas markets such as the United States and Southeast Asia. In addition, the company has multiple products in clinical or preclinical development stages.

For this IPO,艾柯医疗 plans to raise 1.1 billion yuan, which will be used for the production construction project of neurointerventional medical devices, the R&D project of neurointerventional medical devices, the marketing network construction project, and to supplement working capital.

艾柯医疗’s main products have been on the market since December 2022. From 2022 to 2024 and for the first nine months of 2025, the company’s operating revenue was 900,900 yuan, 97.9874 million yuan, 199.9 million yuan, and 188 million yuan, respectively; the net profit attributable to the parent company’s shareholders was -103 million yuan, -363 million yuan, 16.9695 million yuan, and 36.3889 million yuan, respectively.

The actual controllers of艾柯医疗 are 吕树铣 and 吕怡然, who are father and son. Before the IPO, 吕树铣 controlled 32.96% of the company’s shares by serving as the executive partner of 上海蔼祥, while 吕怡然 directly held 4.64% of the company’s shares, controlled 4.60% of the company’s shares through serving as the executive partner of 北京艾驰, and controlled 2.20% of the company’s shares through serving as the executive partner of 上海远霁. Thus, 吕树铣 and 吕怡然 collectively controlled 44.40% of the voting rights in the company through direct shareholding and controlling 上海蔼祥, 北京艾驰, and 上海远霁.

Currently, 吕树铣 serves as the chairman of the company, 吕怡然 serves as the general manager and director, 郭瑞久 serves as the deputy general manager and employee representative director, and 丁邻 serves as the board secretary and financial head.

In terms of compensation, from 2022 to 2024 and for the first nine months of 2025, the total compensation for the directors, the supervisors before the cancellation of the supervisory board, senior management, and core technical personnel of艾柯医疗 was 16.0071 million yuan, 12.6597 million yuan, 13.5085 million yuan, and 9.9032 million yuan, respectively.

According to 瑞财社, the company’s secretary and financial head 丁邻 is a post-75, with extensive experience in the financial sector.

丁邻, born in 1978, is a Chinese national and a permanent resident of Hong Kong. 丁邻 obtained a bachelor’s degree from the外交学院 and a master’s degree from the 高等商学院 in Paris, France. From 2007 to 2016, he served as the vice president of the investment banking department and director of Greater China at BNP PARIBAS SECURITIES (ASIA) LIMITED, and head of natural resources at Citigroup Global Markets Asia Limited in the investment banking department for Greater China; from 2016 to 2021, he worked at 上海复星高科技（集团）有限公司 and 医渡科技有限公司; from 2021 to 2022, he served as the chief financial officer of the company; and since 2022, he has served as the company’s board secretary and financial head.